Our history
The finest moments in a cancer researcher’s life are when all pieces fall into place. An insight. A connection. A molecule that lands just right.
The finest moments in a cancer researcher’s life are when all pieces fall into place. An insight. A connection.
A molecule that lands just right.
One such moment occurred when our founder, Professor Bengt Gustafsson, together with researchers at Merck & Cie, identified a new path forward — one that could enhance the efficacy of established cancer treatments.
The result was arfolitixorin: a patented drug candidate with the potential to change the treatment landscape. The spirit of discovery that led to arfolitixorin lives on in everything we do. With science as our compass and risk awareness guiding every step, we strive to help more patients respond better to treatment, improve their prognosis, and gain more time with life.
Together, we are making tomorrow’s cancer treatment better.
From 2008 to now
2025
Conducting a new clinical phase Ib/II study with arfolitixorin in patients with metastatic colorectal cancer in Germany.
Rights issue.
2024
Solasia intensified its commitment to the continued development of arfolitixorin and plans to expand the upcoming clinical study in Japan.
Collaboration agreement signed with one of Europe’s leading hospitals, Charité – Universitätsmedizin Berlin, to conduct the Phase Ib/II clinical study in Germany.
Presented a clinical development plan for arfolitixorin based on analyses and studies that together form the comprehensive evidence platform completed during the year.
2023
Completed detailed analysis of the AGENT study outcome and possible way forward for the drug candidate arfolitixorin.
Evaluated arfolitixorin in laboratory tests in colorectacl and pancreatic cancer cells.
2022
Analysis of the study data in the AGENT study begins on April 22.
Final data showed that arfolitixorin did not meet either the primary endpoint or the key secondary endpoint.
2021
Interim analysis: iDSMB recommends completion of the AGENT study with 440 patients
All 56 patients, of Japanese descent, recruited
Rights issue
Isofol’s share is listed on Nasdaq Stockholm
Receives Fast Track Designation
2020
New share issue
330 patients reached for interim analysis in the AGENT study
The AGENT study fully enrolled with 440 patients
Licensing agreement signed with Solasia Pharma in Japan
Licensing agreement signed with Paladin in Canada
2019
PMDA and TGA approval of the AGENT study protocol
2018
Established dose, 2×60 mg/m2 for continued development of arfolitixorin in combination with 5-FU
The global phase III study, AGENT, with arfolitixorin begins in the US and Europe
2017
Isofol approved IND (Investigational New Drug) by the FDA
Isofol’s share is listed on Nasdaq First North Premier Growth Market
2016
Regulatory support from FDA and EMA
2013
Signing of license agreements with Merck, and initial partnership with Recipharm
2011
Clinical study begin
2008
The company is founded by Professor Bengt Gustafsson
Last updated: